Double-blind study reveals the effect of Eurcerin actives on atopic dermatitis
Researchers at Beiersdorf have collaborated with the Dermatological Clinic of the University of Lübeck on a double-blind clinical study on Eurcerin’s AtopiControl ingredient complex. The study has confirmed that the Eucerin AtopiControl range provides effective relief from atopic dermatitis.
Adult volunteers suffering with mild to moderate atopic dermatitis, who were symptom-free at the time, were instructed to apply one of either the brand’s lotion or a lotion base without the active ingredients to each arm. Dr Frank Rippke, Researcher and Physician at Beiersdorf, explained: “Neither the study participants nor the doctors knew which side was treated with the active formulation and which side with the active-free lotion base.”
Arms that had been applied with the active had “significantly longer symptom-free intervals” than those that had been using the active-free base. Rippke said: “We were able to prove, for the first time, that the symptom-free intervals in cases of atopic dermatitis can be extended by medical skin care actives.”
The study could have an impact on future treatment for atopic dermatitis, which is a chronic skin care condition causing dry, flaky, red and itchy skin. There is currently no cure, although dermatologists recommend regular intensive skin care to control the condition and protect the skin.
Atopic dermatitis affects up to 5% of adults and up to one in every five children. Dry and sensitive skin can have psychological effects, particularly children who are often subject to teasing. The condition can also cause sleeplessness due to intense itchiness and extreme skin sensitivity.